Serum levels of soluble CD30 improve InternationalPrognostic Score in predicting the outcome of advanced Hodgkin’s lymphoma

Abstract

In our study, the combination of IPS >2 and serum sCD30 levels > or =100 U/ml identifies a sizeable subgroup (18%) of advanced HL patients with very poor FFS, who might take advantage of intensified up-front treatment strategies.

Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes

“…Soluble CD30 (sCD30) is typically elevated in advanced HL (30). Although CD30.CAR-Ts are not blocked by sCD30 (26, 31), we found an inverse correlation (P = 0.0087) between sCD30 levels at the time of CD30.CAR-T infusion and the subsequent expansion of CD30.CAR-Ts ( Figure 6C).…”

“…Notably, in responding patients the peak of CD30.CAR-T molecular signals in peripheral blood coincided with a transient increase of sCD30 consistent with the release of sCD30 upon tumor destruction (ref. 30, Figure 6D, and Supplemental Figure 3C). Finally, numerous reports have described high expression and was deemed to achieve a CR after the fourth infusion that was maintained for 9 months.…”

Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome

“…It also points to the potential use of senescenceinducing drugs in cHL treatment. In addition, we show (although only in the primary cohort) that the two CDKIs may be combined with the mass-dependent parameter sCD30 (3,4) into an even more refined prognostic index (Supplementary Fig. S1; Supplementary Tables S1 and S2).…”

“…Though some clinical and laboratory prognostic markers have been figured out and tested (for example, we have previously described sCD30 as a neoplastic mass index and a reliable prognostic marker; refs. 3,4), it is quite surprising that so far there is no acknowledged biologic feature linked to the degree of malignant behavior of cHL (5)(6)(7). Indeed, the pathogenesis of cHL has been intensively investigated, revealing a biologic heterogeneity that might provide useful information for clinical and prognostic case stratification.…”

Soluble CD22 as a tumor marker for hairy cell leukemia

“…A wide variety of soluble receptors and antigens have been reported associated with malignancies, including soluble granulocyte-monocyte colony-stimulating factor receptor in acute myelogenous leukemia (AML), 1 soluble CD20 in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and Hodgkin disease (HD), 2,3 soluble CD25 (soluble interleukin-2 receptor alpha or sTac) in CD25 ϩ T-and B-cell malignancies, solid tumors and in autoimmune disorders, [4][5][6] soluble CD27 in indolent NHL, 7 soluble CD30 in autoimmune disorders 8 and in HD, 9,10 soluble CD40 in multiple myeloma (MM), CLL, mantle cell lymphoma (MCL), and AML, 11 soluble CD44 in NHL and early CLL, 12 soluble CD52 in CLL, 13 soluble CD80 in CLL and MCL, 14 soluble CD86 in MM and NHL, 15,16 soluble CD137 in leukemias and lymphomas, 3,17 soluble CD138 in MM 18 and CLL, 19 soluble CD307 (IRTA2, FcRH5) in hairy cell leukemia (HCL), MM, CLL, and MCL, 20,21 beta 2 -microglobulin in HD, MM, and solid tumors, [22][23][24] soluble tumor necrosis factor receptor in NHL, 25 and soluble mesothelin in mesotheliomas. 26 However, none of these markers is routinely used in the management of patients with B-cell malignancies.…”